There isn't much need to worry at this stage, its a sit back and...

There isn't much need to worry at this stage, its a sit back and relax point now if you have already bought in. The team is doing well and their pipeline is advancing on all fronts. Readouts are good, they are getting the approvals when needed and patients/researchers reaching out to them for their novel technologies. The team also seems small, efficient and has skin in the game. There is a lot to like about this company.

Don't get too fixated on the price at the moment. Any announcement could send this up significantly. 200k AUD would get the stock price up 60%. Book is very thin at the moment so the appropriate price discovery won't happen until after the next significant update as most long term investors are locked and loaded by now. The risk return based on an expected return analysis with this stock is extreme. However please beware that there is the risk that all three products in the clinic fail. If any of them succeed, these prices will look laughable in hindsight, but its a risk nonetheless in this area of the market. It's not what you would call a safe bet.